Sanofi formed a deal to develop 15 experimental oncology and immunology drugs with Exscientia Plc with possible total payouts of as much as $5.2 billion, allying with a company that uses artificial intelligence to make new medicines.
The Oxford, England-based company will receive $100 million upfront, as well as milestone payments and royalties from successful treatments, the companies said Friday.
